Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...
Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.
Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...
Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID ...
Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted. Mycophenolate mofetil (MMF) reduces the risk of disease progression in patients with immunoglobulin A ...
To determine whether sirolimus (SIR) and cyclosporine (CSP) combined with post-transplantation cyclophosphamide (PTCy), after nonmyeloablative or reduced-intensity conditioning unrelated donor ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Significantly ...
The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...
Renal biopsy. Immunofluorescence microscopy shows predominant IgA staining in the mesangial region of the glomerular. Up to 40% of patients with IgAN progress to end-stage kidney disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results